VDPP, LLC v. FujiFilm Healthcare Americas: 3D Viewing Patent Case Ends in Voluntary Dismissal With Prejudice

Case Overview

In a case that closed as quietly as it opened, VDPP, LLC voluntarily dismissed its patent infringement action against FujiFilm Healthcare Americas Corporation with prejudice — permanently extinguishing its claims under two 3D stereoscopic viewing patents without any adjudicated verdict, damages award, or public settlement disclosure. Filed January 23, 2025, in the U.S. District Court for the Southern District of New York before Chief Judge Edgardo Ramos, the case (No. 1:25-cv-00680) concluded on July 24, 2025, after just 182 days — a notably compressed timeline in patent litigation.

For patent attorneys, IP professionals, and R&D teams operating in the imaging and display technology space, this outcome carries strategic weight that extends well beyond its quiet procedural close. Voluntary dismissals with prejudice, particularly before an answer is filed, often signal significant behind-the-scenes developments — whether licensing negotiations, claim weakness assessments, or commercial realignments. Understanding what drove this result matters for anyone managing 3D imaging patent portfolios or assessing freedom-to-operate risk.

The Parties

Patents at Issue

This case involved two U.S. patents covering proprietary adjustable-filter stereoscopic spectacle technology branded under the “3Deeps” system:

• • U.S. Patent No. 9,699,444 B2 — Continuous adjustable 3Deeps Filter Spectacles for optimized 3Deeps stereoscopic viewing.
• • U.S. Patent No. 9,716,874 B2 — Faster state transitioning for continuous adjustable 3Deeps filter spectacles using multi-layered variable tint materials.

Litigation Timeline & Procedural History

The Southern District of New York was selected as the venue — a jurisdiction with substantial patent litigation docket experience and home to sophisticated IP judicial panels. Chief Judge Edgardo Ramos, a seasoned federal jurist, was assigned, though the case resolved before substantive judicial engagement on the merits.

Critically, FujiFilm Healthcare Americas never filed an answer or a motion for summary judgment during the 182-day pendency. This procedural posture is precisely what enabled VDPP to exercise its right under Federal Rule of Civil Procedure 41(a)(1)(A)(i) — which permits a plaintiff to voluntarily dismiss an action without court order if the defendant has not yet served an answer or motion for summary judgment.

The Verdict & Legal Analysis

Outcome

On July 23, 2025, VDPP, LLC filed a Notice of Voluntary Dismissal pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(i). The dismissal was entered with prejudice as to the asserted patents, meaning VDPP permanently surrendered its right to re-assert U.S. Patent Nos. 9,699,444 and 9,716,874 against FujiFilm Healthcare Americas in any future action. Each party agreed to bear its own costs, expenses, and attorneys’ fees. No damages were awarded; no injunctive relief was granted or sought through adjudication.

Verdict Cause Analysis

Because FujiFilm Healthcare Americas never filed a responsive pleading, no formal claim construction, validity challenge, or infringement analysis was placed on the public record. The legal record reflects an infringement action that was initiated but never substantively contested in open court.

The with-prejudice designation is the most legally consequential element of this dismissal. A dismissal without prejudice would have preserved VDPP’s right to refile. By accepting a with-prejudice outcome — voluntarily — VDPP made a permanent litigation concession. Possible explanations include:

• Resolution through private licensing agreement (undisclosed terms)
• VDPP’s reassessment of claim strength relative to FujiFilm’s product architecture
• Commercial decision to cease assertion of these specific patents against this defendant
• Mutual agreement between parties to resolve commercially without litigation cost

The absence of any fee-shifting or cost allocation to either party (each bearing its own) suggests the dismissal was cooperative rather than adversarial — consistent with a negotiated resolution or strategic withdrawal.

Legal Significance

Under Rule 41(a)(1)(A)(i), voluntary dismissals before answer are self-executing — they take effect upon filing without judicial approval. The with-prejudice designation, however, converts what is normally a plaintiff-favorable procedural tool into a permanent bar. Courts have consistently held (see Semtek International Inc. v. Lockheed Martin Corp., 531 U.S. 497 (2001)) that with-prejudice dismissals carry full res judicata effect.

For the 3D stereoscopic display patent space, this case produces no precedential claim construction or validity ruling — leaving the legal interpretation of these patents’ scope unresolved in the public record.

Strategic Takeaways

For Patent Holders & PAEs:

Early-stage voluntary dismissals with prejudice may reflect pre-litigation due diligence gaps or post-filing claim mapping challenges — conduct thorough infringement mapping before filing. Accepting with-prejudice terms eliminates future assertion leverage against the same defendant — weigh this against licensing value carefully. When a defendant does not answer promptly, it may signal settlement negotiations or strategic delay — monitor procedural timelines accordingly.

For Accused Infringers:

Withholding an answer during negotiation periods can preserve strategic optionality under Rule 41(a)(1)(A)(i). Achieving a with-prejudice dismissal without court adjudication represents a strong defensive outcome — all future claims under those patents by that plaintiff are barred. No fee award was obtained here; consider whether pursuing attorneys’ fees under 35 U.S.C. § 285 in “exceptional cases” would have been viable if litigation had continued.

For R&D & Product Teams:

FujiFilm Healthcare Americas’ 3D imaging products emerged from this litigation without any adverse finding — no injunction, no damages, no validity ruling limiting product development. Teams developing products adjacent to adjustable stereoscopic display technology should conduct FTO analysis against the 3Deeps patent family, as other VDPP licensing activity may continue in this space.